References
- World Health Organization. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. 2018 [cited 2019 Aug 19]. Available from: https://www.who.int/cancer/PRGlobocanFinal.pdf
- Nersesyan H, Slavin KV. Current aproach to cancer pain management: availability and implications of different treatment options. Ther Clin Risk Manag. 2007;3(3):381–400.
- Fischer DJ, Villines D, Kim YO, et al. Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer. 2010;18(7):801–810.
- Brown LF, Kroenke K, Theobald DE, et al. The association of depression and anxiety with health-related quality of life in cancer patients with depression and/or pain. Psychooncology. 2010;19(7):734–741.
- American Cancer Society. Opioids for cancer pain 2019. [cited 2019 Aug 13]. Available from: https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/pain/opioid-pain-medicines-for-cancer-pain.html
- Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014;120(5):1262–1274.
- Gutgsell T, Walsh D, Zhukovsky DS, et al. A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population. Am J Hosp Palliat Care. 2003;20(2):140–148.
- Chiu N, Chiu L, Chow R, et al. Taxane-induced arthralgia and myalgia: A literature review. J Oncol Pharm Pract. 2017;23(1):56–67.
- Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916–3923.
- Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005;23(22):5235–5246.
- Ripamonti CI, Bossi P, Santini D, et al. Pain related to cancer treatments and diagnostic procedures: a no man’s land? Ann Oncol. 2014;25(6):1097–1106.
- Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci. 2012;1248:124–139.
- Drug Enforcement Agency, Departmend of Justice. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III [Rule]. 2002 [cited 2019 Dec 23]. Available from: https://www.deadiversion.usdoj.gov/fed_regs/rules/2002/fr1007.htm
- Swarm RA, Paice JA, Anghelescu DL, et al. Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(8):977–1007.
- Choudhury K, Dasgupta P, Paul N, et al. A comparative study of transdermal buprenorphine and oral morphine in the treatment of chronic pain of malignant origin. Indian J Palliat Care. 2018;24(4):500–504.
- Butrans (buprenorphine) [package insert]. Stamford, CT: Purdue Pharma L.P.; 2014 [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021306s015s019lbl.pdf
- Seifert R, Wenzel-Seifert K, Gether U, et al. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther. 2001;297(3):1218–1226.
- Johnson RE, Eissenberg T, Stitzer ML, et al. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40(1):17–25.
- Jamalian SM, Sotodeh M, Mohaghegh F. Comparison of sublingual buprenorphine and intravenous morphine in reducing bone metastases associated pain in cancer patients. Eur J Transl Myol. 2019;29(2):8098.
- Schmidt-Hansen M, Taubert M, Bromham N, et al. The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ Support Palliat Care. 2016;6(3):292–306.
- Steiner D, Munera C, Hale M, et al. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011;12(11):1163–1173.
- Twycross R, Wilcock A, Howard P, et al. Palliative care formulary (PCF6), 6th. Nottingham: Palliativedrugs.com, 2017 [cited 16 August 2019]. https://www.palliativedrugs.com/assets/pcf6/Prelims_PCF6.pdf
- Mendelson J, Upton RA, Everhart ET, et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37(1):31–37.
- Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825–834.
- Lutfy K, Eitan S, Bryant CD, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003;23(32):10331–10337.
- Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–580.
- Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Brit J Anaesth. 2006;96(5):627–632.
- Drug and Therapeutics Bulletin. QT interval and drug therapy. BMJ. 2016;353:i2732.
- Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med. 2009;43(9):657–662.
- Harris SC, Morganroth J, Ripa SR, et al. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Postgrad Med. 2017;129(1):69–80.
- Kao DP, Haigney MC, Mehler PS, et al., Arrhythmia associated with buprenorphine and methadone reported to the food and drug administration. Addiction. 110(9): 1468–1475. 2015.
- World Health Organization. WHO’s cancer pain ladder for adults. 2019 [cited 2020 Apr 9]. Available from: https://www.who.int/cancer/palliative/painladder/en/
- World Health Organization. WHO guidelines for the pharmicological and radiotherapeutic management of cancer pain in adults and adolescents. [ updated 2018; cited 2020 Apr 9]. Available from: https://apps.who.int/iris/bitstream/handle/10665/279700/9789241550390-eng.pdf?ua=1
- Poulain P, Denier W, Douma J, et al., Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage. 36(2): 117–125. 2008.
- Haefeli M, Elfering A. Pain assessment. Eur Spine J. 2006;15(Suppl 1):S17–24.
- Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-fentanyl comparative trial group. J Pain Symptom Manage. 1997;13(5):254–261.
- Nosek K, Leppert W, Nosek H, et al. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. Drug Des Devel Ther. 2017;11:2409–2419.
- Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids. Ann Oncol. 2016;27(6):1107–1115.
- Corli O, Roberto A, Bennett MI, et al. Nonresponsiveness and susceptibility of opioid side effects related to cancer patients’ clinical characteristics: A post-hoc analysis. Pain Pract. 2018;18(6):748–757.
- Leppert W, Nosek K. Comparison of the quality of life of cancer patients with pain treated with oral controlled-release morphine and oxycodone and transdermal buprenorphine and fentanyl. Curr Pharm Des. 2019;25(30):3216–3224.
- Melilli G, Samolsky Dekel BG, Frenquelli C, et al. Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag. 2014;10(2):85–93.
- Aiyer R, Gulati A, Gungor S, et al. Treatment of chronic pain with various buprenorphine formulations: A systematic review of clinical studies. Anesth Analg. 2018;127(2):529–538.
- National Academies of Sciences, Engineering, and Medicine. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Trends in Opioid Use, Harms, and Treatment. Washington, DC: National Academies Press (US); 2017 [cited 2019 Dec 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK458661/
- Morphine sulfate injection [package insert]. Lake Forrest, IL: Hospira Inc.; 2011 [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202515s000lbl.pdf
- OxyContin (oxycodone) [package insert]. Stamford, CT: Purdue Pharma. 2007 [cited 2020 Apr 9]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020553s059lbl.pdf
- Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice–a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005;21(8):1147–1156.
- Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12(5):379–384.
- Berland DW, Malinoff HL, Weiner MA, et al. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization. Am J Ther. 2013;20(4):316–321.
- Webster L, Gudin J, Raffa RB, et al. Understanding buprenorphine for use in chronic pain: expert opinion. Pain Med. 2020;21(4):714–723.